Y mAbs Therapeutics (YMAB) - Total Liabilities
Based on the latest financial reports, Y mAbs Therapeutics (YMAB) has total liabilities worth $29.72 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Y mAbs Therapeutics asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Y mAbs Therapeutics - Total Liabilities Trend (2016–2024)
This chart illustrates how Y mAbs Therapeutics's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Y mAbs Therapeutics.
Y mAbs Therapeutics Competitors by Total Liabilities
The table below lists competitors of Y mAbs Therapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BridgeBio Oncology Therapeutics, Inc.
NASDAQ:BBOT
|
USA | $45.37 Million |
|
Moura Dubeux Engenharia S.A
SA:MDNE3
|
Brazil | R$3.67 Billion |
|
GDI Integrated
TO:GDI
|
Canada | CA$762.00 Million |
|
Hunan Creator Information Technologies Co Ltd Class A
SHE:300730
|
China | CN¥397.39 Million |
|
Guangdong PAK Corporation Co Ltd
SHE:300625
|
China | CN¥896.13 Million |
|
Unifique Telecomunicações S.A.
SA:FIQE3
|
Brazil | R$1.49 Billion |
|
Duratec Ltd
AU:DUR
|
Australia | AU$208.32 Million |
|
Hamborner REIT AG
XETRA:HABA
|
Germany | €666.28 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Y mAbs Therapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Y mAbs Therapeutics balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Y mAbs Therapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Y mAbs Therapeutics (2016–2024)
The table below shows the annual total liabilities of Y mAbs Therapeutics from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $27.90 Million | +3.78% |
| 2023-12-31 | $26.88 Million | -16.60% |
| 2022-12-31 | $32.23 Million | -1.35% |
| 2021-12-31 | $32.68 Million | +24.67% |
| 2020-12-31 | $26.21 Million | +50.09% |
| 2019-12-31 | $17.46 Million | +53.22% |
| 2018-12-31 | $11.40 Million | +14.26% |
| 2017-12-31 | $9.97 Million | +91.83% |
| 2016-12-31 | $5.20 Million | -- |
About Y mAbs Therapeutics
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-ri… Read more